Advertisement

Table of Contents

February 16, 2017; 129 (7)

INSIDE BLOOD COMMENTARIES

PERSPECTIVE

REVIEW ARTICLE

EVIDENCE-BASED FOCUSED REVIEW

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

  • Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
    Delphine Rea, Franck E. Nicolini, Michel Tulliez, François Guilhot, Joelle Guilhot, Agnès Guerci-Bresler, Martine Gardembas, Valérie Coiteux, Gaelle Guillerm, Laurence Legros, Gabriel Etienne, Jean-Michel Pignon, Bruno Villemagne, Martine Escoffre-Barbe, Jean-Christophe Ianotto, Aude Charbonnier, Hyacinthe Johnson-Ansah, Marie-Pierre Noel, Philippe Rousselot, François-Xavier Mahon and for the France Intergroupe des Leucémies Myéloïdes Chroniques

IMMUNOBIOLOGY

  • iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease
    Zineb Sbihi, Antoine Dossier, David Boutboul, Lionel Galicier, Christophe Parizot, Amandine Emarre, Bénédicte Hoareau, Nicolas Dupin, Anne-Geneviève Marcelin, Anne Oudin, Claire Fieschi, Félix Agbalika, Brigitte Autran, Eric Oksenhendler and Guislaine Carcelain

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

BLOOD WORK

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS